AbCellera Biologics (ABCL) vs Organon (OGN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
AbCellera Biologics (ABCL) has outperformed Organon (OGN) over the past year, gaining 122.4% versus a gain of 30.1%. Over five years, ABCL leads with a -17.4% price change compared with -60.5% for OGN. AbCellera Biologics is the larger company by market cap ($3.87 billion vs $3.62 billion), about 1.1 times the size.
Organon pays a dividend yielding 0.58%, while AbCellera Biologics does not currently pay one. Organon converts more of its revenue into profit, with a net margin of 3.0% versus -194.9%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ABCL | OGN |
|---|---|---|
| Share price | $11.95 | $13.80 |
| Market cap | $3.87B | $3.62B |
| 1-day change | -6.90% | +0.04% |
| YTD return | +275.15% | +92.33% |
| 1-year return | +122.36% | +30.09% |
| 5-year return | -17.39% | -60.48% |
| P/E ratio (TTM) | — | 17.69 |
| Forward P/E | — | 3.82 |
| EPS (TTM) | $-0.54 | $0.78 |
| Dividend yield | 0.00% | 0.58% |
| Annual dividend | $0.00 | $0.08 |
| Revenue (latest FY) | $75.13M | $6.22B |
| Revenue growth (YoY) | +160.56% | -2.92% |
| Net income (latest FY) | $-146.41M | $187.00M |
| Gross margin | — | 53.30% |
| Operating margin | -288.98% | — |
| Net margin | -194.88% | 3.01% |
| 52-week high | $15.02 | $13.80 |
| 52-week low | $2.75 | $5.69 |
| Distance from 52-week high | -20.45% | -0.04% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +39.81% | -18.45% |
| Average volume | 6.67M | 2.64M |
| Shares outstanding | 324.05M | 262.61M |
| Employees | 562 | 10,000 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ABCL has outperformed OGN by 92.3 percentage points over the past year.
- Organon is more profitable, keeping 3.0 cents of every revenue dollar as net income versus -194.9 cents for AbCellera Biologics.
- AbCellera Biologics grew revenue faster in its latest fiscal year (+160.56% vs -2.92%).
About AbCellera Biologics
ABCL stock →AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations · 562 employees
About Organon
OGN stock →Organon & Co. develops and delivers women health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, China, Latin America, the Middle East, Russia, Africa, and internationally.
Health Care · Biotechnology: Pharmaceutical Preparations · 10,000 employees
ABCL vs OGN FAQ
Which is bigger, AbCellera Biologics or Organon?
AbCellera Biologics (ABCL) is larger, with a market capitalization of $3.87B compared with $3.62B for Organon (OGN).
Which stock has performed better over the past year, ABCL or OGN?
ABCL returned +122.36% over the past 12 months, compared with +30.09% for OGN (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, AbCellera Biologics or Organon?
Organon pays a dividend yielding 0.58%, while AbCellera Biologics does not currently pay a regular dividend.
Are AbCellera Biologics and Organon in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.